NR3C2 and hypertensive disorder: Studies in diabetic animal models have demonstrated that mineralocorticoid receptor antagonist (MRA) protection of the heart and kidney is partly due to reducing hypertension but also to reducing inflammation and fibrosis in these organs [5,6].